Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Open Access
- 21 June 2016
- journal article
- review article
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Medicine
- Vol. 6 (8), a026211
- https://doi.org/10.1101/cshperspect.a026211
Abstract
The p53 pathway is perturbed in the majority of human cancers. Although this most frequently occurs through the direct mutation or deletion of p53 itself, there are a number of other alterations that can attenuate the pathway and contribute to tumorigenesis. For example, amplification of important negative regulators, MDM2 and MDM4, occurs in a number of cancers. In this work, we will review both the normal regulation of the p53 pathway and the different mechanisms of pathway inhibition in cancer, discuss these alterations in the context of the global genomic analyses that have been conducted across tumor types, and highlight the translational implications for cancer diagnosis and treatment.Keywords
This publication has 122 references indexed in Scilit:
- The mutational landscape of lethal castration-resistant prostate cancerNature, 2012
- A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor DevelopmentCancer Cell, 2010
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- p53 and MDM2 in renal cell carcinomaCancer, 2010
- The multiple levels of regulation by p53 ubiquitinationCell Death & Differentiation, 2009
- The ubiquitin ligase COP1 is a critical negative regulator of p53Nature, 2004
- Disruption of HAUSP gene stabilizes p53Nature, 2004
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993